Declared Dividend • May 20
Dividend of UK£0.015 announced Shareholders will receive a dividend of UK£0.015. Ex-date: 21st May 2026 Payment date: 22nd June 2026 Dividend yield will be 2.3%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is not adequately covered by earnings (92% earnings payout ratio). However, it is well covered by cash flows (46% cash payout ratio). The dividend has increased by an average of 24% per year over the past 2 years and payments have been stable during that time. The company's earnings per share (EPS) would need to grow by 1.9% to bring the payout ratio under control. EPS is expected to grow by 40% over the next 3 years, which is sufficient to bring the dividend into a sustainable range. Anuncio • Apr 22
NIOX Group Plc, Annual General Meeting, May 21, 2026 NIOX Group Plc, Annual General Meeting, May 21, 2026. Location: the companys registered office magdalen centre, 1 robert robinson ave, the oxford science park, england, ox4 4ga, oxford United Kingdom Anuncio • Mar 25
Niox Group plc Recommends Final Dividend for the Year Ended 31 December 2025 NIOX Group Plc announced that the Board recommended the payment of a final dividend of 1.55 pence per fully paid ordinary share (2024: 1.25 pence). The aggregate amount of the proposed dividend expected to be paid after the reporting date, out of retained earnings at 31 December 2025, but not recognized as a liability at year end is £6.5 million (2024: £5.0 million). Anuncio • Mar 20
NIOX Group Plc to Report Fiscal Year 2025 Results on Mar 24, 2026 NIOX Group Plc announced that they will report fiscal year 2025 results on Mar 24, 2026 Anuncio • Jul 08
NIOX Group Plc to Report First Half, 2025 Results on Sep 30, 2025 NIOX Group Plc announced that they will report first half, 2025 results on Sep 30, 2025 Anuncio • Apr 03
Niox Group plc Recommends Final Dividend for the Year Ended December 31, 2024 NIOX Group Plc recommended final dividend of 1.25 pence per share in respect of the year ended December 31 2024. Anuncio • Mar 21
An unknown funds managed by Keensight Capital made a proposal to acquire NIOX Group Plc (AIM:NIOX) for approximately £320 million. An unknown funds managed by Keensight Capital made a proposal to acquire NIOX Group Plc (AIM:NIOX) for approximately £320 million on February 20, 2025. As on March 6, 2025, The Board of NIOX Group received a revised proposal from Keensight Capital on behalf of funds managed or advised by it ("Keensight") regarding a possible cash offer to acquire the entire issued and to be issued ordinary share capital of NIOX (the "Proposal") at an offer price of £0.81 per NIOX share, the Proposal follows a previous unsolicited approach by Keensight to acquire NIOX on February 20, 2025 at an offer price of £0.78 per NIOX share. The Proposal is subject to the satisfaction or waiver by Keensight of a number of pre-conditions, including the completion of satisfactory due diligence. Accordingly, the Board has agreed to provide Keensight with access to due diligence. Discussions with Keensight remain at a preliminary stage and, as such, there can be no certainty that any firm offer will be made for the Company by Keensight, nor as to the terms of any such offer, should one be made.
Lazard & Co., Limited and Singer Capital Markets Advisory LLP acted as financial advisor to NIOX. Anuncio • Jan 17
NIOX Group Plc, Annual General Meeting, May 14, 2025 NIOX Group Plc, Annual General Meeting, May 14, 2025. Anuncio • Dec 04
NIOX Group Plc to Report Fiscal Year 2024 Results on Apr 01, 2025 NIOX Group Plc announced that they will report fiscal year 2024 results at 8:00 AM, GMT Standard Time on Apr 01, 2025 Reported Earnings • Sep 26
First half 2024 earnings released: EPS: UK£0.01 (vs UK£0.007 in 1H 2023) First half 2024 results: EPS: UK£0.01 (up from UK£0.007 in 1H 2023). Revenue: UK£21.0m (up 12% from 1H 2023). Net income: UK£4.40m (up 52% from 1H 2023). Profit margin: 21% (up from 15% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Anuncio • Sep 24
NIOX Group Plc (AIM:NIOX) announces an Equity Buyback for 26,250,000 shares, representing 6.19% for £21 million. NIOX Group Plc (AIM:NIOX) announces a share repurchase program. Under the program, the company will repurchase up to 26,250,000 shares, representing 6.19% of its share capital for £21 million. The shares will be repurchased at £0.8 per share. The company intends to hold 10,000,000 shares in treasury and the remaining shares will be cancelled. The record date for the offer is October 15, 2024. The offer will be valid till October 15, 2024. The tender offer is subject to approval from shareholders in the Extraordinary General Meeting to be held on October 16, 2024. As of September 23, 2024, the company has 424,045,460 shares in issue. Anuncio • Aug 19
NIOX Group Plc to Report First Half, 2024 Results on Sep 24, 2024 NIOX Group Plc announced that they will report first half, 2024 results on Sep 24, 2024 Anuncio • Jul 01
Niox Group plc Appoints Robert Naylor as Non-Executive Director and Chair of the Audit and Risk Committee NIOX Group plc announced the appointment of Robert Naylor, aged 49, as Non-Executive Director and Chair of the Audit and Risk Committee, with immediate effect. Robert has over 25 years' experience in capital markets specialising in healthcare and investment companies and is currently Chief Executive Officer of Intuitive Investments Group plc, an investment company which is quoted on the Specialist Fund Segment of the London Stock Exchange's Main Market, providing investors with exposure to a portfolio of fast-growing technology and life sciences businesses. Additionally, Robert is Non-Executive Chairman of Hipgnosis Songs Fund Limited, a FTSE 250 company, which is currently subject to a recommended cash offer by Lyra Bidco Limited, a newly-formed company indirectly wholly-owned by investment funds advised by affiliates of Blackstone Inc. Previously, Robert was Non-Executive Chairman of Round Hill Music Royalty Fund Limited and oversaw its sale to a company directly owned by Alchemy Copyrights, LLC, trading as Concord. He has also served as a Non-Executive Director of Light Science Technologies Holdings plc, an AIM-quoted controlled environment agriculture company. Earlier in his career Robert held various positions within JP Morgan Asset Management Limited, Panmure Gordon (UK) Limited and Cenkos Securities plc. Robert is a qualified chartered accountant, having started his career with Ernst & Young in 1996. Current directorships/partnerships: Intuitive Investments Group Plc, IIG Assets Ltd, Hipgnosis SFH XX Limited, Hipgnosis SFH XIII Limited, Hipgnosis SFH XIX Limited, Hipgnosis SFH I Limited, Hipgnosis Holdings UK Limited, Rubyruby (London) Limited, Pb Songs Ltd, Kennedy Publishing & Productions Limited, Deamon Limited. Past directorships/partnerships: Round Hill Music Royalty Fund Limited, RHMRF2 Limited, RHMRF3 Limited, Light Science Technologies Holdings plc, Concord Copyrights No.1 Limited (formerly RHMRF1 Limited). Upcoming Dividend • May 16
Upcoming dividend of UK£0.01 per share Eligible shareholders must have bought the stock before 23 May 2024. Payment date: 24 June 2024. Trailing yield: 1.4%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (1.7%). Anuncio • Apr 05
NIOX Group Plc Proposes Final Dividend for the Financial Year Ended 31 December 2023, Payable on 24 June 2024 NIOX Group Plc announced on 26 March 2024 a proposed final dividend of 1.0 pence per ordinary share in respect of the financial year ended 31 December 2023. The proposed dividend is subject to shareholder approval at the Company's Annual General Meeting ("AGM") to be held on 22 May 2024. Following approval, the dividend will be paid on 24 June 2024 to shareholders on the register at the close of business on the record date of 24 May 2024, with an ex-dividend date of 23 May 2024. Recent Insider Transactions • Mar 31
COO & Executive Director recently sold €171k worth of stock On the 28th of March, Jonathan Emms sold around 234k shares on-market at roughly €0.73 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Jonathan's only on-market trade for the last 12 months. Reported Earnings • Mar 26
Full year 2023 earnings released Full year 2023 results: Revenue: UK£36.8m (up 18% from FY 2022). Net income: UK£9.50m (down 33% from FY 2022). Profit margin: 26% (down from 45% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Germany. Reported Earnings • Sep 28
First half 2023 earnings released: EPS: UK£0.007 (vs UK£0.021 in 1H 2022) First half 2023 results: EPS: UK£0.007 (down from UK£0.021 in 1H 2022). Revenue: UK£18.8m (up 21% from 1H 2022). Net income: UK£2.90m (down 67% from 1H 2022). Profit margin: 15% (down from 57% in 1H 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has only increased by 42% per year, which means it is significantly lagging earnings growth. New Risk • Sep 27
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 23% Last year net profit margin: 46% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (23% net profit margin). Anuncio • Jul 21
NIOX Group Plc Announces Special Dividend, Payable on 15 September 2023 NIOX Group Plc announced a special dividend of 2.5 pence per share (equating to a return of cash of approximately £10.5 million) will be paid on 15 September 2023 to shareholders on the register as at the close of business on Friday 18 August 2023. The Group is now generating sufficient operating cashflow to permit both continued investment in the development of its business and the payment of ongoing dividends to shareholders. Anuncio • Jun 07
NIOX Group Plc Announces Special Dividend, Payable on 15 September 2023 NIOX Group Plc announced that a special dividend of 2.5 pence per ordinary share will be paid on 15 September 2023 to shareholders on the register as at 18 August 2023. The associated ex-dividend date will be 17 August 2023. Board Change • Apr 02
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Non-Independent Non-Executive Director Nick Mills was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Mar 30
COO & Executive Director recently sold €114k worth of stock On the 28th of March, Jonathan Emms sold around 227k shares on-market at roughly €0.50 per share. This transaction amounted to 24% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Jonathan's only on-market trade for the last 12 months. Reported Earnings • Mar 22
Full year 2022 earnings released: EPS: UK£0.034 (vs UK£0.006 in FY 2021) Full year 2022 results: EPS: UK£0.034 (up from UK£0.006 in FY 2021). Revenue: UK£31.3m (up 12% from FY 2021). Net income: UK£14.1m (up UK£11.8m from FY 2021). Profit margin: 45% (up from 8.2% in FY 2021). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has only increased by 50% per year, which means it is significantly lagging earnings growth. Anuncio • Jan 17
NIOX Group Plc to Report Fiscal Year 2022 Results on Mar 21, 2023 NIOX Group Plc announced that they will report fiscal year 2022 results on Mar 21, 2023 Board Change • Oct 31
High number of new directors Non-Independent Non-Executive Director Nick Mills was the last director to join the board, commencing their role in 2020. Reported Earnings • Sep 16
First half 2022 earnings released: EPS: UK£0 (vs UK£0.005 loss in 1H 2021) First half 2022 results: EPS: UK£0 (improved from UK£0.005 loss in 1H 2021). Revenue: UK£15.5m (up 6.2% from 1H 2021). Net income: UK£8.90m (up UK£10.9m from 1H 2021). Profit margin: 57% (up from net loss in 1H 2021). The move to profitability was primarily driven by lower expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany. Anuncio • Jul 14
Circassia Group Plc to Report First Half, 2022 Results on Sep 14, 2022 Circassia Group Plc announced that they will report first half, 2022 results on Sep 14, 2022 Board Change • Apr 27
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non-Independent Non-Executive Director Nick Mills was the last director to join the board, commencing their role in 2020. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Anuncio • Apr 14
Circassia Group Plc, Annual General Meeting, May 13, 2022 Circassia Group Plc, Annual General Meeting, May 13, 2022, at 09:00 Coordinated Universal Time. Location: Northbrook House, Robert Robinson Avenue, Oxford Science park Oxford United Kingdom Recent Insider Transactions • Apr 02
Executive Chairman recently bought €64k worth of stock On the 29th of March, Ian Johnson bought around 150k shares on-market at roughly €0.43 per share. This was the largest purchase by an insider in the last 3 months. Ian has been a buyer over the last 12 months, purchasing a net total of €197k worth in shares. Reported Earnings • Sep 18
First half 2021 earnings released: UK£0.005 loss per share (vs UK£0.027 loss in 1H 2020) The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: UK£14.6m (up 28% from 1H 2020). Net loss: UK£2.00m (loss narrowed 79% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Sep 18
Executive Chairman recently bought €65k worth of stock On the 16th of September, Ian Johnson bought around 150k shares on-market at roughly €0.43 per share. This was the largest purchase by an insider in the last 3 months. Ian has been a buyer over the last 12 months, purchasing a net total of €133k worth in shares. Anuncio • May 27
Beyond Air, Inc. Enters into Settlement Agreement with Circassia Group plc On May 26, 2021, Beyond Air, Inc. entered into a settlement agreement with Circassia Group plc. Under the terms of the Settlement Agreement, the Company retains United States and China commercialization rights to LungFit® PH in exchange for returning $10.5 million in upfront and milestone payments received by the Company in 2019, over a two-year period commencing after the LungFit® PH receives United States Food and Drug Administration approval. Beginning in year three post-approval, Circassia will receive a quarterly royalty payment equal to 5% of LungFit® net sales in the United States, which will terminate once the aggregate payment reaches $6.0 million. The Company now holds full global rights to LungFit® PH. Recent Insider Transactions • Apr 08
Executive Chairman recently bought €67k worth of stock On the 6th of April, Ian Johnson bought around 200k shares on-market at roughly €0.34 per share. This was the largest purchase by an insider in the last 3 months. Ian has been a buyer over the last 12 months, purchasing a net total of €120k worth in shares. Reported Earnings • Mar 25
Full year 2020 earnings released: UK£0.072 loss per share (vs UK£0.13 loss in FY 2019) The company reported a soft full year result with weaker revenues and control over costs, although losses reduced. Full year 2020 results: Revenue: UK£23.9m (down 62% from FY 2019). Net loss: UK£26.8m (loss narrowed 45% from FY 2019). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings. Anuncio • Jan 28
Circassia Group Plc(AIM:CIR) dropped from FTSE All-Share Index (GBP) Circassia Group Plc(AIM:CIR) dropped from FTSE All-Share Index (GBP) Anuncio • Nov 13
Circassia Group Plc Appoints Nicholas Mills as Non-Executive Director Circassia Group Plc announced the appointment of Nicholas Mills as Non-Executive Director, effective 13 November 2020. Nicholas is employed by Harwood Capital LLP. Nicholas joined Harwood Capital LLP in 2019 after spending five years at Gabelli Asset Management in New York. He acted primarily as a Research Analyst covering the multi-industrial space and also gained experience in Merger Arbitrage strategies and marketing Closed End Funds. Anuncio • Sep 02
An unknown buyer acquired 3.4% stake in Circassia Group Plc (AIM:CIR) from CIP Merchant Capital Limited (AIM:CIP) managed by Merchant Capital Manager Limited for £3.9 million. An unknown buyer acquired 3.4% stake in Circassia Group Plc (AIM:CIR) from CIP Merchant Capital Limited (AIM:CIP) managed by Merchant Capital Manager Limited for £3.9 million on September 1, 2020.
An unknown buyer completed the acquisition of 3.4% stake in Circassia Group Plc (AIM:CIR) from CIP Merchant Capital Limited (AIM:CIP) managed by Merchant Capital Manager Limited on September 1, 2020. 
